Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases

Trial Profile

Prospective, randomized, open-label,clinical trial comparing the effects of aliskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine (Primary)
  • Indications Essential hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2011 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
    • 03 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top